Literature DB >> 3013657

Morphine tolerance increases mu-noncompetitive delta binding sites.

R B Rothman, J A Danks, A E Jacobson, T R Burke, K C Rice, F C Tortella, J W Holaday.   

Abstract

In light of more recent knowledge concerning endogenous opioid peptides and their multiple opiate receptors, we reevaluated the effects of morphine tolerance on opiate receptor binding parameters. Rats were implanted with morphine or placebo pellets, and [3H][D-Ala2,D-Leu5]enkephalin ([3H]DADL) was used to label brain membranes. Utilizing the technique of binding surface analysis, we observed a selective 47% up-regulation of lower affinity [3H]DADL binding sites (mu-noncompetitive delta binding sites) in morphine pelleted rats. To corroborate these results, we treated brain membranes with the site directed alkylating agent FIT (N-phenyl-N-[1-(2-p-isothiocyanato)phenyl-ethyl)-4-piperidinyl] propanamide), which results in membranes highly enriched with the lower affinity [3H]DADL binding site. Scatchard plots of [3H]DADL binding to FIT-treated membranes also revealed that chronic morphine treatment produced a 60-65% up-regulation of the mu-noncompetitive delta binding site. These data indicate that chronic morphine alters a selective subpopulation of opiate receptors that may play a role in the mechanisms of opiate tolerance and physical dependence.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3013657     DOI: 10.1016/0014-2999(86)90130-5

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  8 in total

1.  Chronic methadone treatment shows a better cost/benefit ratio than chronic morphine in mice.

Authors:  Johan Enquist; Madeline Ferwerda; Laura Milan-Lobo; Jennifer L Whistler
Journal:  J Pharmacol Exp Ther       Date:  2011-11-07       Impact factor: 4.030

2.  Evolution of the Bifunctional Lead μ Agonist / δ Antagonist Containing the Dmt-Tic Opioid Pharmacophore.

Authors:  Gianfranco Balboni; Severo Salvadori; Claudio Trapella; Brian I Knapp; Jean M Bidlack; Lawrence H Lazarus; Xuemei Peng; John L Neumeyer
Journal:  ACS Chem Neurosci       Date:  2010-02-17       Impact factor: 4.418

3.  Prolonged morphine treatment targets delta opioid receptors to neuronal plasma membranes and enhances delta-mediated antinociception.

Authors:  C M Cahill; A Morinville; M C Lee; J P Vincent; B Collier; A Beaudet
Journal:  J Neurosci       Date:  2001-10-01       Impact factor: 6.167

Review 4.  Opioid peptide-derived analgesics.

Authors:  Peter W Schiller
Journal:  AAPS J       Date:  2005-10-14       Impact factor: 4.009

5.  Regulation of opioid tolerance by let-7 family microRNA targeting the mu opioid receptor.

Authors:  Ying He; Cheng Yang; Chelsea M Kirkmire; Zaijie Jim Wang
Journal:  J Neurosci       Date:  2010-07-28       Impact factor: 6.167

Review 6.  Bi- or multifunctional opioid peptide drugs.

Authors:  Peter W Schiller
Journal:  Life Sci       Date:  2009-03-11       Impact factor: 5.037

7.  The interaction of the mu-opioid receptor and G protein is altered after chronic morphine treatment in rats.

Authors:  P L Tao; C R Lee; P Y Law; H H Loh
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-11       Impact factor: 3.000

Review 8.  Novel Roles of Non-Coding RNAs in Opioid Signaling and Cardioprotection.

Authors:  Zesergio Melo; Cecilia Ishida; Maria de la Paz Goldaraz; Rocio Rojo; Raquel Echavarria
Journal:  Noncoding RNA       Date:  2018-09-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.